Clinical Trial Update: Long Term Study of Canakinumab (ACZ885) in Patients With Gout [Phase 2]

View source ↗

Summary

Phase 2 long-term study of canakinumab in gouty arthritis has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gouty Arthritis

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gouty Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2021-06-09